• Korean Circulation Journal
• /
• 제52권7호
• /
• pp.529-540
• /
• 2022

Background and Objectives: Limited data are available regarding long-term clinical outcomes of iliac artery endovascular therapy (EVT) in real-world practice. This study investigated long-term outcomes according to Trans-Atlantic Inter-Society Consensus (TASC) classifications. Methods: We analyzed data from 1,705 limbs of 1,364 patients from the retrospective cohort of the multicenter Korean Vascular Intervention Society Endovascular Therapy in Lower Limb Artery Disease registry. The primary endpoint was target lesion revascularization (TLR)-free survival. Results: TASC A, B, C, and D lesions were present in 19.4%, 26.2%, 28.7%, and 25.7% of the treated limbs, respectively. The technical success rate was 96.2% and did not differ between TASC lesion types. Complications occurred in 6.8% of cases and more occurred in TASC D (11.8%). Iliac artery EVT showed a 5-year TLR-free survival of 89.2%. The TASC D group had the lowest TLR-free rate of 79.3%. TASC D (hazard ratio [HR], 1.75; 95% confidence interval [CI], 1.12-2.73; p=0.014), plain old balloon angioplasty (HR, 4.25; 95% CI, 2.03-8.88; p<0.001), current smoker (HR, 1.89; 95% CI, 1.26-2.83; p=0.002), previous bypass surgery (HR, 3.04; 95% CI, 1.28-7.19; p=0.011), combined femoropopliteal treatment (HR, 4.89; 95% CI, 3.19-7.50; p<0.001), combined below the knee treatment (HR, 2.20; 95% CI, 1.25-3.89; p=0.007), and complications (HR, 1.86; 95% CI, 1.07-3.24; p=0.028) were predictors for TLR. Conclusions: Iliac artery EVT achieved excellent technical success and 5-year TLR-free survival. TASC D showed a favorable but lower 5-year TLR-free survival rate and higher complication rate compared with other TASC groups.

• Korean Circulation Journal
• /
• 제54권7호
• /
• pp.409-421
• /
• 2024

Background and Objectives: The recent developments in chronic thromboembolic pulmonary hypertension (CTEPH) are emphasizing the multidisciplinary team. We report on the changes in clinical practice following the development of a multidisciplinary team, based on our 7 years of experience. Methods: Multidisciplinary team was established in 2015 offering both balloon pulmonary angioplasty (BPA) and pulmonary endarterectomy (PEA) with technical upgrades by internal and external expertise. For operable cases, PEA was recommended as the primary treatment modality, followed by pulmonary angiography and right heart catheterization after 6 months to evaluate treatment effect and identify patients requiring further BPA. For patients with inoperable anatomy or high surgical risk, BPA was recommended as the initial treatment modality. Patient data and clinical outcomes were closely monitored. Results: The number of CTEPH treatments rapidly increased and postoperative survival improved after team development. Before the team, 38 patients were treated by PEA for 18 years; however, 125 patients were treated by PEA or BPA after the team for 7 years. The number of PEA performed was 64 and that of BPA 342 sessions. World Health Organization functional class I or II was achieved in 93% of patients. The patients treated with PEA was younger, male dominant, higher pulmonary artery pressure, and smaller cardiac index, than BPA-only patients. In-hospital death after PEA was only 1 case and none after BPA. Conclusions: The balanced development of BPA and PEA through a multidisciplinary team approach proved synergistic in increasing the number of actively treated CTEPH patients and improving clinical outcomes.

• Korean Circulation Journal
• /
• 제54권9호
• /
• pp.565-576
• /
• 2024

Background and Objectives: The K-ELUVIA study aimed to investigate the clinical effectiveness and safety of Eluvia^TM, a polymer-coated, paclitaxel-eluting stent, for femoropopliteal artery disease using data from a prospective Korean multicenter registry. Methods: A total of 105 patients with femoropopliteal artery disease who received endovascular treatment (EVT) with Eluvia^TM stents at 7 Korean sites were enrolled in a prospective cohort and followed for 2 years. The primary endpoint was the 2-year clinical patency. The secondary endpoint was 2-year freedom from clinically driven target lesion revascularization (TLR). Results: Mean patient age was 68.2±10.4 years, and most patients (82.7%) were male. Mean lesion length was 168.3±117.6 mm. Chronic total occlusion was found in 57.7% of patients. Trans-Atlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) type C or D lesions were present in 46.1% of patients. Procedural success was achieved in 99.0% of patients. The clinical patency rate was 84.4% at 1 year after EVT and 76.3% at 2 years post-EVT. The freedom from TLR rate was 89.1% at 1 year after EVT and 79.1% at 2 years post-EVT. Chronic total occlusion (hazard ratio [HR], 3.53; 95% confidence interval [CI], 1.08-11.67; p=0.039) and smaller mean stent diameter (HR, 0.40; 95% CI, 0.16-0.98; p=0.044) were identified as independent predictors of loss of clinical patency at 2 years. Conclusions: The K-ELUVIA study demonstrated favorable 2-year clinical effectiveness and safety outcomes of Eluvia stent for femoropopliteal artery lesions in real-world practice.

• Journal of Chest Surgery
• /
• 제32권9호
• /
• pp.781-789
• /
• 1999

배경 및 목적: 폐동맥밴딩술(pulmonary artery banding)은 폐동맥밴딩에 따른 합병증과 2차 수술시의 사망률에 있어서 상당한 위험부담을 갖고 있다. 이에 본 연구에서는 폐동맥밴딩술후에 시행되는 2차 수술의 위험부담을 알아보기 위해서 이전에 폐동맥밴딩술을 받았던 소아에게 시행된 2차 완전교정술의 성적을 조사하였다. 방법: 이전에 폐동맥밴딩술을 받았던 환아들중 1988년 5월부터 1997년 6월사이에 개심술에 의한 2차 완전교정술을 받았던 29례의 소아를 대상으로 하였다. 연령은 생후 2개월에서 45개월까지 였다(평균 20.6$\pm$9.0개월). 이들중 27례는 기왕의 폐동맥밴딩술후에 심부전 증상이 호전되었던 예들이었고(정기 수술군), 2례는 그렇지 못하여 조기에 2차 수술을 시행해야 했었다(조기 수술군). 술전 진단명은 양대혈관우심실기시가 2례(양대혈관우심실기시군), 심실중격결손이 주병변이었던 경우가 27례(심실중격결손군)였었다. 결과: 폐동맥밴딩술후 2차 완전교정술 시행까지의 기간은 5일부터 45개월까지로 평균 15.5$\pm$8.7개월이었다. 수술방법은 양대혈관우심실기시 2례중 1례에서는 심실내 턴넬교정법이, 1례에서는 수정 Glenn수술이 시술되었고, 심실중격결손군에서는 전례에서 심실중격결손의 첨포봉합을 함과 아울러 누두부근육절제술 4례 및 형성부전성 폐동맥판막의 판막절제술 1례가 추가시행되었다. 2차 완전교정술시에, 18례에서는 폐동맥밴딩으로 인해 초래된 협착을 해소하기 위해서 폐동맥패취성형술을 시행하였고, 1례에서는 수정 Glenn수술을 위해 주폐동맥을 근위부에서 완전결찰하였다. 2차 완전교정술에 따른 병원사망률은 17.2%(5례)였는데, 사망원인으로는 저심박출 4례 및 자가면역 출혈성 빈혈 1례가 있었다. 본 연구에 있어서, 양대혈관우심실기시군(2례)과 조기 2차 수술군(2례)은 높은 병원사망률을 나타내는 위험인자로 작용하였다. 그리고 만기사망 1례가 있었다. 결론: 본 연구에서 이전에 폐동맥밴딩술을 받았던 소아에게 2차 완전교정술을 시행했던 결과는 폐동맥밴딩에 따른 후천적 병변을 함께 교정해야 하는 어려움에 기인하여 술후 이병률과 조기 수술사망률이 상당히 높게 나타났다. 따라서 가능하면, 단순 심실중격결손에 있어서는 1차 완전교정술이 요망된다.

• 생명과학회지
• /
• 제26권2호
• /
• pp.226-233
• /
• 2016

혈관평활근세포의 세포자멸사는 죽상경화증을 비롯한 여러 혈관질환에서 일어나며, 죽상판의 불안정화에 중요한 역할을 한다. Oxysterol은 혈관평활근세포의 세포자멸사를 야기하는데, 죽상경화 병변에는 비효소적으로 생성되는 주된 oxysterol인 7-ketocholesterol (7KC)이 대량 존재한다고 알려져 있다. 그러나 7KC에 의한 혈관평활근세포의 세포자멸사에 관하여 밝혀진 자세한 기전은 아직 미흡하다. 본 연구는 7KC가 혈관평활근세포의 세포자멸사를 일으키는 기전을 구명하고자 하였다. Sprague-Dawley계 숫쥐의 대동맥 절편으로부터 배양한 혈관평활근세포에 7KC를 처리하여 혈관평활근세포의 생존력의 변동과 세포자멸사를 각각 methylthiazole tetrazolium bromide 분석법 및 trypan blue 분석법 그리고 유세포 분석법, 면역 형광 측정법, 면역침전법 및 웨스턴블럿 등으로 측정하였다. 7KC는 혈관평활근세포의 생존력을 시간- 및 농도-의존적으로 감소시켰고, 혈관평활근세포내에 지질과산화 최종산물인 4-hydroxynonenal (HNE) 생성을 증가시켰으며, HNE 단독 처리 또한 혈관평활근세포의 생존력을 농도-의존적으로 감소시켰다. 7KC 또는 HNE에 의하여 감소되었던 혈관평활근세포의 생존력은 HNE 생성 억제제인 2,4-dinitrophenyl hydrazine 전처치에 의하여 회복되었다. 더욱이 세포생존 매개인자로 잘 알려져 있는 Akt의 발현이 7KC와 HNE에 의하여 농도-의존적으로 감소되었고, 2,4-dinitrophenyl hydrazine 또는 N-acetylcysteine 전처치에 의하여 회복되었다. 단백질분해효소복합체 억제제인 lactacystin은 7KC에 의한 세포자멸사와 Akt 감소는 억제하였지만 7KC에 의한 HNE 생성은 억제하지 못하였다. HNE에 결합된 Akt의 양은 7KC와 HNE에 의하여 현저히 증가하였으며 단백질분해효소복합체 억제제인 lactacystin 전처치 시에도 유의하게 증가하였다. 이상의 결과로 보아 죽상경화 병변에서 7KC는 혈관평활근세포내 HNE 생성을 증가시키고, 이 HNE에 결합된 Akt는 단백질분해효소복합체에 의하여 분해되는 것으로 보이며, 이와 같은 기전에 의하여 죽상판의 불안정화가 촉진되는 것으로 생각된다.

• Korean Circulation Journal
• /
• 제54권4호
• /
• pp.189-200
• /
• 2024

Background and Objectives: Concerns remain that early aspirin cessation may be associated with potential harm in subsets at high risk of ischemic events. This study aimed to assess the effects of P2Y12 inhibitor monotherapy after 3-month dual antiplatelet therapy (DAPT) vs. prolonged DAPT (12-month or longer) based on the ischemic risk stratification, the CHADS-P2A2RC, after percutaneous coronary intervention (PCI). Methods: This was a sub-study of the SMART-CHOICE trial. The effect of the randomized antiplatelet strategies was assessed across 3 CHADS-P2A2RC risk score categories. The primary outcome was a major adverse cardiac and cerebral event (MACCE), a composite of all-cause death, myocardial infarction, or stroke. Results: Up to 3 years, the high CHADS-P2A2RC risk score group had the highest incidence of MACCE (105 [12.1%], adjusted hazard ratio [HR], 2.927; 95% confidence interval [CI], 1.358-6.309; p=0.006) followed by moderate-risk (40 [1.4%], adjusted HR, 1.786; 95% CI, 0.868-3.674; p=0.115) and low-risk (9 [0.5%], reference). In secondary analyses, P2Y12 inhibitor monotherapy reduced the Bleeding Academic Research Consortium (BARC) types 2, 3, or 5 bleeding without increasing the risk of MACCE as compared with prolonged DAPT across the 3 CHADS-P2A2RC risk strata without significant interaction term (interaction p for MACCE=0.705 and interaction p for BARC types 2, 3, or 5 bleeding=0.055). Conclusions: The CHADS-P2A2RC risk score is valuable in discriminating high-ischemic-risk patients. Even in such patients with a high risk of ischemic events, P2Y12 inhibitor monotherapy was associated with a lower incidence of bleeding without increased risk of ischemic events compared with prolonged DAPT.